Mitsubishi Tanabe Pharma issues its news to provide stakeholders with the latest information related to the Company. Information on products or drug candidates may be included, but is intended to provide for the media, etc. It is not intended for promotion, advertising or medical advice. Information is current as of the date of issue of the individual news. Please be advised that information may be outdated after that point.
Information Mitsubishi Tanabe Pharma Included in the Dow Jones Sustainability Asia Pacific Index
September 18, 2019
Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka; President & Representative Director: Masayuki Mitsuka) announced that it has been included for two consecutive years in the Dow Jones Sustainability Asia Pacific Index, the Asia Pacific subset of Dow Jones Sustainability Indices (DJSI).
DJSI are the representative ESG investment indices developed by Dow Jones of the U.S. and RobecoSAM of Switzerland and evaluate corporate sustainability from the three aspects of environmental, society and governance.
The external evaluations of our company’s CSR activities are listed here.
We will continue striving to realize a sustainable society by fulfilling corporate social responsibility in our business activities.
